

# Hypertension in pediatric patients admitted to inpatient ward at King Abdulaziz University Hospital in Saudi Arabia: Prevalence, causes, and outcomes

## Osama Safdar, Reham AlJehani, Mohammed Aljuhani, Hajar AlGhamdi, Arub Asiri, Oyoon AlGhofaily, Fatimah Hisan, Ghidah Altabsh

Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia

#### ABSTRACT

**Background:** The secondary hypertension (HTN) is the predominant form of HTN in pediatrics. Renal diseases and renovascular anomalies are the most commonly reported causes. In this study, we aimed to identify the prevalence, causes, and outcomes of secondary HTN in Saudi Arabia. **Methods:** A retrospective study was conducted among 3,640 pediatric patients aged between 0 and 18 years, admitted to the pediatric nephrology ward at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. The study has been approved by the ethics review committee of King Abdulaziz University. **Results:** Prevalence of secondary HTN due to renal disease was (77.0%). Most of the cases were diagnosed with stage 5 renal disease (78.3%). Small kidney size was frequently diagnosed (*n* = 29, 11.9%), followed by large kidney size (*n* = 26, 10.7%). One third of the cases (*n* = 79, 32.4%) were under control, 49 (20.1%) lost follow-up, and 24 (10.1%) deceased. A total of 61 (33.1%) patients progressed to end-stage renal disease is considered to be high in pediatric patients admitted to King Abdulaziz University. Several renal diseases in the renal system are associated with secondary HTN mostly attributed to renal malformation. In addition, renal affection, cerebral infarction, bleeding, left ventricular hypertrophy, and valvular lesion are the highest reported complications in our population. Follow-up with ECHO and brain CT is highly recommended in pediatric HTN. Future studies on a larger sample and vigorous follow-up are recommended.

Keywords: Hypertension, pediatric, inpatient, outcomes

## Introduction

Hypertension (HTN) is identified as persistent blood pressure values  $\geq$ the 95<sup>th</sup> percentile. Primary HTN has no definite secondary causes but multiple factors such as obesity, insulin resistance, impairment in sodium homeostasis, or renin-angiotensin system may be involved.<sup>[1]</sup> Secondary HTN, in

Address for correspondence: Dr. Osama Safdar, Department of Pediatrics, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia. E-mail: safderosama@hotmail.com

**Received:** 05-02-2020 **Accepted:** 26-03-2020 **Revised:** 13-03-2020 **Published:** 25-08-2020

Acce	ss this article online
Quick Response Code:	Website: www.jfmpc.com
	DOI: 10.4103/jfmpc.jfmpc_214_20

contrast, is the predominant form of HTN, and the underlying etiology lies behind various secondary causes.<sup>[2]</sup> In a retrospective review, out of 275 hypertensive children, 57% had secondary HTN due to renal, cardiovascular, autoimmune, endocrine, gastrointestinal, hematological, medication-related orneurological causes.<sup>[3]</sup>

Management guidelines of pediatric HTN were updated in 2017, the disease is recognized by elevated blood pressure >90<sup>th</sup> percentile; early detection and management measurements are essential to lessen the irreversible changes that could affect the cardiovascular system and renal system.<sup>[2,4]</sup> Calcium-channel

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: WKHLRPMedknow\_reprints@wolterskluwer.com

**How to cite this article:** Safdar O, AlJehani R, Aljuhani M, AlGhamdi H, Asiri A, AlGhofaily O, *et al.* Hypertension in pediatric patients admitted to inpatient ward at King Abdulaziz Universty Hospital in Saudi Arabia: Prevalence, causes, and outcomes. J Family Med Prim Care 2020;9:4031-8.

blockers (CCB) and angiotensin-converting enzyme inhibitors (ACEI) are the most favorable therapy to lower blood pressure in pediatric.<sup>[4,5]</sup> However, secondary HTN was found to have a better response than primary HTN.<sup>[5]</sup>

The complication of HTN are miscellaneous, HTN could be presented as hypertensive emergency that may involve severe kidney injury, affection of myocardium, and retinopathy.<sup>[6]</sup> In a retrospective study carried out on 246 children with sustained HTN, 35 patients were presented, for the first time, with complications of severe HTN such as congestive heart failure and encephalopathy. The underlying causes of HTN in is this study were attributed to renal, renovascular, or endocrine system disorders.<sup>[7]</sup>

Pediatric population in the Kingdom of Saudi Arabia is highly susceptible to develop either primary or secondary HTN, hence regular screening is highly recommended. In a recent study that aimed outline the prevalence of risk factors of diabetes and HTN among school children in Kingdom of Saudi Arabia, 11.6% had body mass index (BMI) above the normal range and 43% had sedentary lifestyle.<sup>[8]</sup> In a cross-sectional study of 401 adolescents from Jeddah, the prevalence of HTN was 17.2%, pre-HTN was observed in 4.2%, and obesity was reported in 19.2%. In addition, the prevalence of hematuria and proteinuria were 17% and 10.2%, respectively.<sup>[9]</sup> In a recently published article, isolated systolic hypertension (ISH) was the most reported phenotype in obese children (24.3%).<sup>[10]</sup>

However there are no studies assess the prevalence of HTN in pediatric patients addmitted to pediatric inpatient ward. Consequently, in our present study, we sought to assess the prevalence, causes, and outcomes of secondary HTN in pediatric patients admitted to King Abdulaziz University Hospital in Jeddah, Saudi Arabia between 2015 and 2019.

## **Material and Methods**

#### Study setting

This is a retrospective study, conducted among 3,640 pediatric patients in the pediatric ward at King Abdulaziz University Hospital, Jeddah, Saudi Arabia. Patients aged 0-18 years of age were included. The study has been approved by the ethics review committee of King Abdulaziz University June 14, 2017. For the age group (1-13), the American Academy of Pediatrics (AAP) updated guidelines 2017 has been followed to diagnose HTN which is: Normal BP: <90th percentile. Elevated BP:  $\geq 90^{\text{th}}$  percentile to  $< 95^{\text{th}}$  percentile or 120/80mmHg to <95<sup>th</sup> percentile or 130/80 to 139/89 mm Hg. Stage 1 HTN:  $\geq 95^{\text{th}}$  percentile to  $< 95^{\text{th}}$  percentile + 12 mmHg. Stage 2 HTN: ≥95th percentile +12 mmHg, or 2140/90 mm Hg. For the  $\geq$ 13 age group, adolescent same as adults, American Heart Association (AHA) guidelines have eliminated the category of preHTN, categorizing patients as having either Elevated (120-129 and less than 80) or stage I HTN (130-139 or 80-89). While previous guidelines classified 140/90 mm Hg as stage 1 HTN, this level is classified as stage 2 HTN under the new guidelines.<sup>[4]</sup>

## Data collection

Data were obtained by an electronic questionnaire from pediatric ER, pediatric medical ward, and Pediatric intensive care unit (ICU) files, in the period 2010–2018 at King Abdulaziz University Hospital. The questionnaire included information about gender, age at diagnosis, HTN causes, renal disease stage, blood pressure, HTN urgency, HTN emergency, complication, medical history, laboratory investigation, ultrasound, kidney size, renal disease characteristic, cardiovascular, CT brain, renal CT, medication, past history, and outcomes.

## Data analysis

Data entry was performed by Microsoft Excel. Descriptive analysis was performed using the SPSS software. Qualitative variables were summarized by calculating the number and percent, whereas the median, 25<sup>th</sup> and 75<sup>th</sup> Quartile range were calculated for continuous variables.

## Results

Out of 3,640 participants, 244 met the criteria for the diagnosis of HTN, 86 patients (35.2%) were female and 158 (64.8%) were male, the mean age was 10 years. Third of the cases (n = 86, 35.2%) were diagnosed at the age between 0 and 2 years, then at the age 6 and 10 years (n = 64, 26.2%).

## Prevalence of secondary HTN and its causes

The majority of the cases (n = 188, 77.0%) were secondary to kidney disease, then primary cause in (n = 23, 9.4%) cases. Most of the cases were diagnosed with stage 5 renal disease (78.3%). Less than half of the case were HTN urgency (n = 59, 24.2%) and HTN emergency (n = 49, 20.1%). Total of 170 (69.7%) patients did not perform CT brain, 40 (16.4%) had normal CT brain, only 34 (13.9%) had abnormal CT brain and only 4 (1.6%) cases had eye problems. The majority 236 (96.7%) of cases did not have any birth complications. Table 1 summarizes the demographic and baseline character of included patients. Past history of chronic illness is insulted in Figure 1, 48 (17.1%) had "nephrotic syndrome," followed by 32 (11.4%) "Renal diseases," then 12 (43%) "Hematological diseases."

## Renal

Regarding laboratory and radiological investigations, there was a decrease in serum levels of P, K, and creatinine. While there was an increase in the levels of Calcium (Ca) electrolytes, Magnesium (Mg), glomerular filtration rate (GFR), GFR2, bicarb, and Albumin. On the other hand, the level of PH, RBCs, and protein decreased [Table 2].

Total of 55 (22.5%) did not perform an ultrasound, normal ultrasound was noted in (45.1%), while bi-lateral hydronephrosis in (16.4%) and unilateral hydronephrosis in (6.6%), different findings are presented in Table 3.

Regarding kidney size, total of 56 (22.9%) showed that there is no data about kidney size, 121 (49.6%) had normal kidney size, while

Female       86         Male       158         Age by Median, (25 <sup>th</sup> and 75 <sup>th</sup> Quartile range)       10.0         ge at diagnosis       92         0-2       86         3-5       50         6-10       64         11-15       41         16-18       3         TN causes       2         Cardiac       2         Neuroblastoma       1         Primary       23         Secondary (Endocrine)       22         Secondary (CNS)       11         Secondary (CNS)       14         Stage 1       10         Stage 2       4         Stage 1       10         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       ////////////////////////////////////	Percentag	n	included patients Variable
Male       158         Age by Median, $(25^{th} and 75^{th} Quartile range)       10.0         ge at diagnosis       10.0         Gato       64         11-15       41         16-18       3         Strong       1         Primary       23         Secondary (Endocrine)       2         Secondary (Kidney disease)       188         Secondary (CNS)       11         Secondary (medications)       1         Secondary (colications)       1         Secondary to stress       2         Transient       14         enal disease stage       10         Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       1         /A       216         < 95^{th} + 5       1         10/130. 108/55       1         11  $			Gender
Age by Median, (25 <sup>th</sup> and 75 <sup>th</sup> Quartile range)       10.0         ge at diagnosis       9.2         0-2       86         3.5       50         6-10       64         11-15       41         16-18       3         TN causes       2         Cardiac       2         Neuroblastoma       1         Primary       23         Secondary (Endocrine)       2         Secondary (Midney disease)       188         Secondary (CNS)       11         Secondary (medications)       1         Secondary to stress       2         Transient       14         enal disease stage       10         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       1         /A       216         <95 <sup>th</sup> 1         >95 <sup>th</sup> 1         10/130. 108/55       1         11       1         90 <sup>th</sup> 1         90 <sup>th</sup> 1         90 <sup>th</sup> 1 </td <td>35.2</td> <td>86</td> <td>Female</td>	35.2	86	Female
ge at diagnosis $9-2$ 86 $0-2$ $5$ $50$ $6-10$ $64$ $11-15$ $41$ $16-18$ $3$ TN causes $2$ Cardiac $2$ Neuroblastoma $1$ Primary $23$ Secondary (Endocrine) $2$ Secondary (medications) $11$ Secondary to stress $2$ Transient $14$ enal disease stage       Not applicable         Not applicable $141$ Stage 1 $10$ Stage 2 $4$ Stage 3 $5$ Stage 4 $6$ Stage 5 $78$ lood pressure chart $/A$ $/A$ $216$ $95^{5h}$ $1$ $20/67$ $1$ $10/130. 108/55$ $1$ $20/67$ $1$ $10/9^{5h}$ $1$ $92^{5h} + 5$ $1$ $92^{5h} + 5$ $1$ $92^{5h} + 5$ $1$ $92^$	64.8	158	Male
ge at diagnosis $9-2$ 86 $0-2$ $5$ $50$ $6-10$ $64$ $11-15$ $41$ $16-18$ $3$ TN causes $2$ Cardiac $2$ Neuroblastoma $1$ Primary $23$ Secondary (Endocrine) $2$ Secondary (medications) $11$ Secondary to stress $2$ Transient $14$ enal disease stage       Not applicable         Not applicable $141$ Stage 1 $10$ Stage 2 $4$ Stage 3 $5$ Stage 4 $6$ Stage 5 $78$ lood pressure chart $/A$ $/A$ $216$ $95^{5h}$ $1$ $20/67$ $1$ $10/130. 108/55$ $1$ $20/67$ $1$ $10/9^{5h}$ $1$ $92^{5h} + 5$ $1$ $92^{5h} + 5$ $1$ $92^{5h} + 5$ $1$ $92^$	(5, 15)	10.0	Age by Median, (25 <sup>th</sup> and 75 <sup>th</sup> Quartile range)
$0.2$ 86 $3.5$ 50 $6.10$ 64 $11-15$ 41 $16.18$ 3         TN causes       2         Cardiac       2         Neuroblastoma       1         Primary       23         Secondary (Endocrine)       2         Secondary (cNS)       11         Secondary to stress       2         Transient       14         enal disease stage       10         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       //         /A       216 $< 95^h$ 1 $20/67$ 1 $120/67$ 1 $120/67$ 1 $120/67$ 1 $120/67$ 1 $120/67$ 1 $120/67$ 1 $120/67$ 1 $120/67$ 1 $120/67$ 1 $120/9^h + 5$ 5			
$6-10$ $64$ $11-15$ $41$ $16-18$ $3$ TN causes $2$ Cardiac $2$ Neuroblastoma $1$ Primary $23$ Secondary (Endocrine) $2$ Secondary (Kidney disease) $188$ Secondary (NS) $11$ Secondary to stress $2$ Transient $14$ nansient $14$ Stage 1 $10$ Stage 2 $4$ Stage 3 $5$ Stage 4 $6$ Stage 5 $78$ kood pressure chart $//$ $/A$ $216$ $< 95^{h}$ $1$ $>99^{h} + 5$ $4$ $10/130. 108/55$ $1$ $20/67$ $1$ $185/90. 160/68$ $1$ $90^{h} + 5$ $1$ $99^{h} + 5$ $1$ $99^{h} + 5$ $1$ $99^{h} + 5$ $1$ $99^{h} + 5$ $5$ $10$ $10$	35.2	86	0-2
11-154116-183ITN causes2Cardiac2Neuroblastoma1Primary23Secondary (Endocrine)2Secondary (Kidney disease)188Secondary (CNS)11Secondary (medications)1Secondary to stress2Transient14enal disease stageNot applicableNot applicable141Stage 110Stage 24Stage 35Stage 46Stage 578lood pressure chart1/A216 $<95^{ah}$ 1 $>99^{ah} + 5$ 4110/130. 108/551120/671185/90. 160/68150^{ah}199^{ah} + 5199^{ah} + 5199^{ah} + 55ITN urgency1No185Yes49omplications1Non236hyaline membrane disease3prolonged ventilation >4 weeks1	20.5	50	3-5
16-183ITN causes2Cardiac2Neuroblastoma1Primary23Secondary (Endocrine)2Secondary (Kidney disease)188Secondary (CNS)11Secondary (medications)1Secondary to stress2Transient14enal disease stage10Not applicable141Stage 110Stage 24Stage 35Stage 46Stage 578lood pressure chart1/A216 $<95^{h}$ 1>95 centrile1>99^{h} + 54110/130. 108/551120/671185/90. 160/681 $5^{h}$ 199^{h} + 5199^{h} + 5199^{h} + 55ITN urgency1No185Yes49omplications185Yes49omplications236hyaline membrane disease3prolonged ventilation >4 weeks1	26.2	64	6-10
TIN causesCardiac2Neuroblastoma1Primary23Secondary (Endocrine)2Secondary (Kidney disease)188Secondary (CNS)11Secondary (medications)1Secondary to stress2Transient14enal disease stage10Stage 110Stage 24Stage 35Stage 46Solge 578lood pressure chart1/A216 $< 95^{th}$ 1>99^{th} + 54110/130.108/551120/671185/90.160/68150^{th}190^{th}1 <td>16.8</td> <td>41</td> <td>11-15</td>	16.8	41	11-15
Cardiac       2         Neuroblastoma       1         Primary       23         Secondary (Endocrine)       2         Secondary (Kidney disease)       188         Secondary (CNS)       11         Secondary (medications)       1         Secondary to stress       2         Transient       14         enal disease stage       10         Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       //         /A       216         <95 <sup>th</sup> 1         >90 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         50 <sup>th</sup> 3         5 <sup>th</sup> 1         93/140       1         93 <sup>th</sup> 1         93 <sup>t</sup>	1.2	3	16-18
Neuroblastoma 1 Primary 23 Secondary (Endocrine) 2 Secondary (Kidney disease) 188 Secondary (NS) 11 Secondary (medications) 1 Secondary to stress 2 Transient 14 enal disease stage Not applicable 141 Stage 1 10 Stage 2 4 Stage 3 5 Stage 4 6 Stage 5 78 lood pressure chart /A 216 $< 95^{th}$ 1 $>95^{th}$ 1 10/130.108/55 1 120/67 1 120/67 1 120/67 1 $150^{th}$ 3 $5^{th}$ 1 $150^{th}$ 3 $5^{th}$ 1 120/67 1 $150^{th}$ 3 $5^{th}$ 1 120/67 1 $150^{th}$ 3 $5^{th}$ 1 100 1 $95^{th}$ 4 $495^{th} + 5$ 5 TTN urgency No 185 Yes 59 TTN emergency No 195 Yes 49 omplications Non 236 hyaline membrane disease 3 prolonged ventilation >4 weeks 1			HTN causes
Primary       23         Secondary (Endocrine)       2         Secondary (Kidney disease)       188         Secondary (CNS)       11         Secondary (medications)       1         Secondary to stress       2         Transient       14         enal disease stage       10         Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       //         /A       216         <95 <sup>th</sup> 1         >99 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         5 <sup>th</sup> 1         90 <sup>th</sup> 1         92 <sup>th</sup> 5         17       1         92 <sup>th</sup>	0.6	2	Cardiac
Secondary (Endocrine)       2         Secondary (Kidney disease)       188         Secondary (CNS)       11         Secondary (medications)       1         Secondary to stress       2         Transient       14         enal disease stage       10         Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       //         /A       216 $< 95^{h}$ 1         >99 <sup>h</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         5 <sup>h</sup> 1         90 <sup>h</sup> 1         90 <sup>h</sup> 1         92 <sup>h</sup> 1         90 <sup>h</sup> 1         92 <sup>h</sup> 5         ITM urgency       1         No       185         Yes       59         ITN urgency       1         No       195         Yes       49         omplications <td>0.3</td> <td>1</td> <td>Neuroblastoma</td>	0.3	1	Neuroblastoma
Secondary (Endocrine)       2         Secondary (Kidney disease)       188         Secondary (CNS)       11         Secondary (medications)       1         Secondary to stress       2         Transient       14         enal disease stage       10         Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       //         /A       216 $< 95^{h}$ 1         >99^{h} + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         5 <sup>h</sup> 1         90 <sup>h</sup> 1         92 <sup>h</sup> 5         17       1         92 <sup>h</sup> 5         17N urgency <t< td=""><td>9.4</td><td>23</td><td>Primary</td></t<>	9.4	23	Primary
Secondary (Kidney disease)188Secondary (CNS)11Secondary to stress2Transient14enal disease stage10Not applicable141Stage 110Stage 24Stage 35Stage 46Stage 578lood pressure chart1/A216 $<95^{th}$ 1 $>99^{th} + 5$ 4110/130. 108/551120/671185/90. 160/681 $5^{th}$ 199199191/140195^{th}5ITN urgency1No185Yes59ITN emergency1No195Yes49omplications125Yes33polonged ventilation >4 weeks3prolonged ventilation >4 weeks1	.8	2	
Secondary (CNS)       11         Secondary (medications)       1         Secondary to stress       2         Transient       14         enal disease stage       141         Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       7         /A       216         <95 <sup>th</sup> 1         >95 centrile       1         >99 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         50 <sup>th</sup> 3         5 <sup>th</sup> 1         120/67       1         185/90. 160/68       1         50 <sup>th</sup> 3         5 <sup>th</sup> 1         92 <sup>th</sup> + 5       1         92 <sup>th</sup> + 5       5         17M urgency       1         No       185         Yes       59         ITN emergency       1         No       195         Yes       49 <td>77.0</td> <td>188</td> <td></td>	77.0	188	
Secondary (medications)       1         Secondary to stress       2         Transient       14         enal disease stage       141         Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       //         /A       216         <95 <sup>th</sup> 1         >95 centrile       1         >90 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         5 <sup>th</sup> 1         90 <sup>th</sup> 1         92 <sup>th</sup> 4         92 <sup>th</sup> 1         90 <sup>th</sup> 1         92 <sup>th</sup> 1         92 <sup>th</sup> 1         92 <sup>th</sup> 5         17N urgency       1         No       185         Yes       59         17N emergency       1         No       195         Yes       49         omplications       3      <	с	11	
Secondary to stress       2         Transient       14         enal disease stage       141         Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       7         /A       216         <95 <sup>th</sup> 1         >95 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         5 <sup>th</sup> 1         100       1         93/140       1         95 <sup>th</sup> + 5       1         99 <sup>th</sup> + 5       5         TTN urgency       1         No       185         Yes       49         omplications       195         Yes       49         omplications       3         Non       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	.4	1	
Transient       14         enal disease stage       141         Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       //         /A       216         <95 <sup>th</sup> 1         >90 <sup>th</sup> + 5       4         110/130.108/55       1         120/67       1         185/90.160/68       1         5 <sup>th</sup> 1         90 <sup>th</sup> 1         93/140       1         95 <sup>th</sup> 1         99 <sup>th</sup> 5         TN urgency       1         No       185         Yes       59         TN emergency       195         Yes       49         omplications       3         Non       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	.8	2	
Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       //         /A       216 $< 95^{h}$ 1         >95 centrile       1         >99^{h} + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         5 <sup>th</sup> 1         90 <sup>th</sup> 3         5 <sup>th</sup> 1         90 <sup>th</sup> 1         93/140       1         95 <sup>th</sup> 1         95 <sup>th</sup> 1         90 <sup>th</sup> 5         ITN urgency       1         No       185         Yes       59         ITN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	5.7	14	Transient
Not applicable       141         Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       //         /A       216 $< 95^{h}$ 1         >95 centrile       1         >99^{h} + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         5 <sup>th</sup> 1         90 <sup>th</sup> 3         5 <sup>th</sup> 1         90 <sup>th</sup> 1         93/140       1         95 <sup>th</sup> 1         95 <sup>th</sup> 1         90 <sup>th</sup> 5         ITN urgency       1         No       185         Yes       59         ITN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1			Renal disease stage
Stage 1       10         Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       7         /A       216 $< 95^{h}$ 1         >95 centrile       1         >99 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         5 <sup>th</sup> 1         75 <sup>th</sup> centrile       1         90       1         93/140       1         95 <sup>th</sup> + 5       1         99 <sup>th</sup> + 5       5         TTN urgency       1         No       185         Yes       59         TTN emergency       195         Yes       59         TN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	57.8	141	
Stage 2       4         Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       78         /A       216 $< 95^{h}$ 1         >95 centrile       1         >90 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         5 <sup>th</sup> 1         75 <sup>th</sup> centrile       1         90       1         93/140       1         95 <sup>th</sup> 1         99 <sup>th</sup> 1         99 <sup>th</sup> 5         17N urgency       1         No       185         Yes       59         TIN emergency       195         Yes       59         Vin emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	4.1	10	
Stage 3       5         Stage 4       6         Stage 5       78         lood pressure chart       216 $< 95^{\text{th}}$ 1         >95 centrile       1         >99 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         50 <sup>th</sup> 3         5 <sup>th</sup> 1         75 <sup>th</sup> centrile       1         90       1         93/140       1         95 <sup>th</sup> + 5       1         99 <sup>th</sup> + 5       5         TIN urgency       1         No       185         Yes       59         TIN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	1.6	4	
Stage 4       6         Stage 5       78         lood pressure chart       216 $\langle 95^{th} \rangle$ 1         >95 centrile       1         >99 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         50 <sup>th</sup> 3         5 <sup>th</sup> 1         75 <sup>th</sup> centrile       1         90       1         93/140       1         95 <sup>th</sup> 4         95 <sup>th</sup> 1         99 <sup>th</sup> + 5       5         TIN urgency       1         No       185         Yes       59         TIN emergency       195         Yes       59         Viron       195         Yes       39         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	2.0	5	
Stage 5       78         lood pressure chart       216 $\langle 95^{th} \rangle$ 1         >95 centrile       1         >99 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         50 <sup>th</sup> 3         5 <sup>th</sup> 1         90       1         93/140       1         95 <sup>th</sup> 4         95 <sup>th</sup> 1         99 <sup>th</sup> + 5       5         TIN urgency       1         No       185         Yes       59         TIN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	2.5	6	-
lood pressure chart       /A       216 $< 95^{th}$ 1         >95 centrile       1         >99 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1 $50^{th}$ 3 $5^{th}$ 1         75 <sup>th</sup> centrile       1         90       1         93/140       1         95 <sup>th</sup> 4         95 <sup>th</sup> 1         90 <sup>th</sup> 5         TIN urgency       1         No       185         Yes       59         TIN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	32.0	78	-
/A       216         <95 <sup>th</sup> 1         >95 centrile       1         >90 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1         50 <sup>th</sup> 3         5 <sup>th</sup> 1         75 <sup>th</sup> centrile       1         90       1         93/140       1         95 <sup>th</sup> + 5       1         90 <sup>th</sup> + 5       5         TTN urgency       1         No       185         Yes       59         TTN emergency       185         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1			-
>95 centrile       1         >99 <sup>th</sup> + 5       4         110/130. 108/55       1         120/67       1         185/90. 160/68       1 $50^{th}$ 3 $5^{th}$ 1         75 <sup>th</sup> centrile       1         90       1         93/140       1         95 <sup>th</sup> + 5       1         95 <sup>th</sup> + 5       1         99 <sup>th</sup> 1         99 <sup>th</sup> + 5       5         TTN urgency       V         No       185         Yes       59         TIN emergency       V         No       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	88.5	216	
>99 <sup>th</sup> + 5       4 $110/130.\ 108/55$ 1 $120/67$ 1 $185/90.\ 160/68$ 1 $50^{th}$ 3 $5^{th}$ 1 $75^{th}$ centrile       1 $90$ 1 $93/140$ 1 $95^{th}$ 4 $95^{th}$ 4 $95^{th}$ 1 $99^{th}$ 1 $99^{th}$ 1 $99^{th}$ 5         ITN urgency       V         No       185         Yes       59         ITN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	.4	1	<95 <sup>th</sup>
$110/130.\ 108/55$ 1 $120/67$ 1 $185/90.\ 160/68$ 1 $50^{th}$ 3 $5^{th}$ 1 $75^{th}$ centrile1 $90$ 1 $93/140$ 1 $95^{th}$ 4 $95^{th}$ 1 $99^{th}$ 1 $99^{th}$ 5I'N urgency5No185Yes59I'N emergency195Yes49omplications236hyaline membrane disease3prolonged ventilation >4 weeks1	.4	1	>95 centrile
$\begin{array}{ccccc} 1 \\ 1 \\ 185/90.\ 160/68 & 1 \\ 50^{\rm th} & 3 \\ 5^{\rm th} & 1 \\ 75^{\rm th} \ centrile & 1 \\ 90 & 1 \\ 93/140 & 1 \\ 93/140 & 1 \\ 95^{\rm th} & 4 \\ 95^{\rm th} + 5 & 1 \\ 99^{\rm th} & 1 \\ 99^{\rm th} & 1 \\ 99^{\rm th} & 5 \\ 1 \\ 99^{\rm th} & 5 \\ 71^{\rm N} \ urgency \\ No & 185 \\ Yes & 59 \\ 71^{\rm N} \ emergency \\ No & 195 \\ Yes & 49 \\ omplications \\ Non & 236 \\ hyaline \ membrane \ disease \\ 3 \\ prolonged \ ventilation >4 \ weeks \\ 1 \\ \end{array}$	1.6	4	>99 <sup>th</sup> + 5
$\begin{array}{ccccc} 1 \\ 1 \\ 185/90.\ 160/68 & 1 \\ 50^{\rm th} & 3 \\ 5^{\rm th} & 1 \\ 75^{\rm th} \ centrile & 1 \\ 90 & 1 \\ 93/140 & 1 \\ 93/140 & 1 \\ 95^{\rm th} & 4 \\ 95^{\rm th} + 5 & 1 \\ 99^{\rm th} & 1 \\ 99^{\rm th} & 1 \\ 99^{\rm th} & 5 \\ 1 \\ 99^{\rm th} & 5 \\ 71^{\rm N} \ urgency \\ No & 185 \\ Yes & 59 \\ 71^{\rm N} \ emergency \\ No & 195 \\ Yes & 49 \\ omplications \\ Non & 236 \\ hyaline \ membrane \ disease \\ 3 \\ prolonged \ ventilation >4 \ weeks \\ 1 \\ \end{array}$	.4	1	110/130. 108/55
$50^{h}$ 3 $5^{h}$ 1 $75^{th}$ centrile       1 $90$ 1 $93/140$ 1 $95^{th}$ 4 $95^{th}$ 1 $99^{th}$ 1 $99^{th}$ 1 $99^{th}$ 5         ITN urgency       V         No       185         Yes       59         ITN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	.4	1	
$50^{h}$ 3 $5^{h}$ 1 $75^{th}$ centrile       1 $90$ 1 $93/140$ 1 $95^{th}$ 4 $95^{th}$ 1 $99^{th}$ 1 $99^{th}$ 1 $99^{th}$ 5         ITN urgency       V         No       185         Yes       59         ITN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	.4	1	185/90.160/68
$5^{th}$ centrile       1 $90$ 1 $93/140$ 1 $95^{th}$ 4 $95^{th}$ 1 $99^{th}$ 1 $99^{th}$ 5         ITN urgency       5         No       185         Yes       59         ITN emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	1.2	3	50 <sup>th</sup>
90       1 $93/140$ 1 $95^{th}$ 4 $95^{th}$ 1 $99^{th}$ 1 $99^{th}$ 5         I'I'N urgency       5         No       185         Yes       59         I'N emergency       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	.4		5 <sup>th</sup>
$\begin{array}{cccc} 93/140 & 1 \\ 95^{\rm th} & 4 \\ 95^{\rm th} + 5 & 1 \\ 99^{\rm th} & 1 \\ 99^{\rm th} + 5 & 5 \\ TTN \ urgency & & \\ No & 185 \\ Yes & 59 \\ TTN \ emergency & & \\ No & 195 \\ Yes & 49 \\ omplications & & \\ Non & 236 \\ hyaline \ membrane \ disease & 3 \\ prolonged \ ventilation >4 \ weeks & 1 \\ \end{array}$	.4	1	75 <sup>th</sup> centrile
$95^{th} + 5$ 4 $95^{th} + 5$ 1 $99^{th}$ 1 $99^{th} + 5$ 5         I'IN urgency       1         No       185         Yes       59         I'IN emergency       1         No       195         Yes       49         omplications       236         hyaline membrane disease       3         prolonged ventilation >4 weeks       1	.4	1	90
$95^{th} + 5$ 1 $99^{th}$ 1 $99^{th} + 5$ 5I'I'N urgency185Yes59I'I'N emergency70No195Yes49omplications236hyaline membrane disease3prolonged ventilation >4 weeks1	.4	1	93/140
$99^{h}$ 1 $99^{h}$ + 55ITN urgency185Yes59ITN emergency717No195Yes49omplications236hyaline membrane disease3prolonged ventilation >4 weeks1	1.6	4	95 <sup>th</sup>
99th + 55ITN urgency185Yes59ITN emergency717No195Yes49omplications236hyaline membrane disease3prolonged ventilation >4 weeks1	.4	1	$95^{th} + 5$
TIN urgency No 185 Yes 59 TIN emergency No 195 Yes 49 omplications Non 236 hyaline membrane disease 3 prolonged ventilation >4 weeks 1	.4	1	99 <sup>th</sup>
No185Yes59ITN emergency195Yes49omplications236hyaline membrane disease3prolonged ventilation >4 weeks1	2.0	5	$99^{\text{th}} + 5$
Yes 59 ITN emergency 59 No 195 Yes 49 omplications 236 hyaline membrane disease 3 prolonged ventilation >4 weeks 1			HTN urgency
TN emergency 195 No 195 Yes 49 omplications 236 hyaline membrane disease 3 prolonged ventilation >4 weeks 1	75.8	185	No
No195Yes49omplications236Non236hyaline membrane disease3prolonged ventilation >4 weeks1	24.2	59	Yes
No195Yes49omplications236Non236hyaline membrane disease3prolonged ventilation >4 weeks1			HTN emergency
omplicationsNon236hyaline membrane disease3prolonged ventilation >4 weeks1	79.9	195	No
Non236hyaline membrane disease3prolonged ventilation >4 weeks1	20.1	49	Yes
Non236hyaline membrane disease3prolonged ventilation >4 weeks1			Complications
prolonged ventilation >4 weeks 1	96.7	236	Non
prolonged ventilation >4 weeks 1	1.2	3	hyaline membrane disease
	.4	1	prolonged ventilation >4 weeks
3000515 4	1.6	4	Sepsis

Table 1: Contd			
Variable	n	Percentage	
CT brain final			
Not applicable	170	69.7	
Abnormal	34	13.9	
Normal	40	16.4	
Eye examination			
Not applicable	214	87.7	
Blind	3	1.2	
Fundis exam was performed, D, M, V WNL, pt not	1	.4	
coaprative			
Normal	26	10.7	
Mode of delivery			
Unknown	212	86.9	
C/S	8	3.3	
	24	9.8	
GA			
Unknown	233	95.5	
24-28	1	.4	
33-36	10	4.1	

C/S, cesarean section; SVD, spontaneous vaginal delivery; GA, gestational age




Figure 1: Frequencies of chronic illness in patients past history

the rest 67 (27.5%) had different findings; small kidney size was frequently diagnosed (n = 29, 11.9%), followed by large kidney size (n = 26, 10.7%). Good corticomedullary differentiation was reported in (59%) while poor in (13.9%), absence of nephrocalcinosis in (73.8%) while it presented in only (2.5%). The majority of cases did not perform micturating cystourethrogram (MCUG) (n = 209, 85.6%), normal finding in (6.6%) while bilateral vesicoureteral reflux was present in 8 cases (3.3%) and unilateral vesicoureteral reflux in 4 cases only. Total of 85.1% did not perform dimercaptosuccinic acid (DMSA) scan, normal finding in (5.7%). Total of 218 (89.6%) did not perform CT renal, 5 (2.0%) had normal CT renal, while only 21 (8.4%) had different findings. Characteristic of renal imaging are presented in Table 4.

## CVS

The results in Table 5 summarize findings in CVS; there were 157 (65.5%) cases who did not perform ECHO, 52 (21.3%)

Table 2: Laboratory investigation in included patients			
Variable	Median	25th and 75th Quartile range	
Ca initial	2.18	(2.0,2.3)	
Ca last	2.24	(2.0,2.3)	
P initial	1.57	(1.3,1.9)	
P last	1.52	(1.2,1.8)	
K initial	4.20	(3.8,4.9)	
K last	4.0	(3.6,4.4)	
Ca initial electrolytes	2.1	(1.8,2.4)	
Ca last electrolytes	2.2	(1.9,2.3)	
Mg initial	0.8	(0.7,0.9)	
Mg last	0.9	(0.7,1.0)	
Alb initial	27.0	(17.0,33.0)	
Alb last	31.0	(23.0,36.0)	
RBCs initial	2.0	(0.9,10.0)	
RBCs last	2.0	(1.0,14.0)	
Protein initial	2.0	(1.0,3.0)	
Protein last	2.0	(1.0,3.0)	
Creatinine initial	53.5	(28.8,164.0)	
Creatinine last	50.0	(30.0,269.0)	
GFR initial	95.7	(45.1,146.9)	
GFR last	197.2	(102.2,245.2)	
PH initial	7.33	(7.2,7.4)	
PH last	7.34	(7.2,7.4)	
Bicarb initial	23.0	(18.0,25.6)	
Bicarb last	24.0	(20.8,27.0)	
GFR initial 2	7.5	(2.7,15.3)	
GFR last 2	9.1	(1.4,15.1)	

Table 3: Ultrasound finding			
Variable	n	Percentage	
Not done	55	22.5	
Normal	110	45.1	
ARPCKD	1	.4	
Atrophic left kidney	1	.4	
bi-lateral hydronephrosis	40	16.4	
Bilateral atrophy	1	.4	
Bilateral Hydroureter	1	.4	
bilateral minimal fullness of renal pelvis	1	.4	
Bilateral small echogenic kidney with RT renal cortical cyst	1	.4	
Bilateral small echogenic kidneys with mild to	1	.4	
moderate ascites			
Bilateral small hydrocele	1	.4	
Ectopic right kidney	1	.4	
hyperechoic	1	.4	
hyperechoic and multiple cyst on both	1	.4	
Increase echogenesty bilatral	1	.4	
increase Echogenicity	1	.4	
increase echogenicty	1	.4	
Increase right renal echogenicity	1	.4	
Kidney stones	1	.4	
Left multicystic kidney	1	.4	
mild prominence of calyceal system	1	.4	
Multiple cysts	1	.4	
Polycystic kidney	1	.4	
Severe Hydroureters	1	.4	
small echogenic kidneys	1	.4	
Stable polycrystic disease	1	.4	
uni-lateral hydronephrosis	16	6.6	

had normal echo, while only 35 (13.2%) had different findings presented in the table; left ventricular hypertrophy in 10 cases followed by valvular lesion in six cases and PDA in two cases.

## Brain

The results in Table 6 summarize the findings in the brain; there were 169 (69.3%) patients who did not perform CT brain, 40 (16.4%) had normal finding, while only 35 (14.3%) had different findings; infarction in six cases and bleeding in two cases.

## Medication

Only 11 (2.6%) patients did not receive any medications, while the rest received different type of medications; 134 (31.3%) received "ACE inhibitors," followed by 123 (28.7%) administered "Diuretics (furosemide)," then 106 (24.8%) had "Ca- channel blockers." Figure 2.

## Disease progression and outcomes

One-third of the cases (n = 79, 32.4%) were under control while 49 (20.1%) lost follow-up and 24 (10.1%) deceased. Total of 61 (33.1%) were progressed to end-stage renal disease and patients were managed by different types of treatments; 20 cases were managed by medications, 19 cases were managed by hemodialysis, and 17 cases were managed by peritoneal dialysis [Table 7].

## Discussion

There is a lack of knowledge regarding th eprevalence of HTN in children of Saudi Arabia. This study findings document the prevalence, causes, and outcomes of HTN in pediatric patients presented in the inpatient ward. Out of 244 included patients, 188 cases had HTN secondary to renal disease with a prevalence of 77.0% while the prevalence of primary HTN was 9.4%. Half of the patients were diagnosed in the first 5 years. Nephrotic syndrome and renal diseases were the most frequent chronic illness that had been reported, which explain the abnormalities in renal imaging and renal function test. However, the reported data




Figure 2: Frequencies of medications used in patients

Table 4: Characteristics of	ot renal imaging		
Variable		n	Percentage
k	Cidney size		
Normal		121	49.6
no data		56	22.9
$5.6 \times 3$ cm size of the left kidne		1	.4
A large right sided abdominal m		1	.4
measuring approxumately 6.5 tim			
times in diameter, located in the	expected region of		
the right adrenal gland Big		26	10.7
Lt kidny atrophied, Rt kidny enla	raed	1	.4
Minimal increase in the size	ugeu	1	.4
Relatively increased		1	.4
right kidney only		1	.4
Right kidneys is small		1	.4
Rt is small		1	.4
Rt. is small, Lt. is big		1	.4
Small		29	11.9
The right is normal		1	.4
The right kidney enlarged		1	.4
With cyst measures 0.5 cm		1	.4
	dullary differentiation	-	
NA	authory arrestoriation	57	23.3
Normal		1	.4
cortical thickness		2	.8
Cortical thickness of 0.8		1	.4
Good		144	59.0
good in the right		2	.8
increased cortical echogenicity		1	.4
Irregular outline with multiple di	verticulae	1	.4
Mild cortical increase echogenici		1	.4
or stones			
Poor		34	13.9
Nep	hrocarcinosis		
Absent		180	73.8
N/A		58	23.7
Present		6	2.5
	MCUG		
Not applicable		209	85.6
Normal		16	6.6
bi-lateral vesicoureteral reflux		8	3.3
Bladder is distended and elongat	ed	1	.4
Grade 5 right sided vesicoureteri	c reflux	1	.4
Grade V		1	.4
Neurogenic bladder		1	.4
Neurogenic bladder with no vest	coureteric reflux	1	.4
Normal but the patient may have bladder	e neurogenic	1	.4
Obstruction		1	.4
Uni-lateral vesicoureteral reflux		4	1.6
	DMSA		
Normal		14	5.7
Not applicable		217	85.1
bi-lateral scarring		5	2.0
evidance of bilatral renal impairs	ment, wore on the	1	.4
no evidence of functioning tissu	e at the left side on	1	.4
the right side			Contd

Table 4: Contd		
Variable	n	Percentage
Right double moiety collecting system with dilated	1	.4
non obstructed system and preserved split function		
Right normal/left multicystic dysplastic kidney	1	.4
small rt kidney but no scar	1	.4
uni-lateral scarring	3	1.2
Renal CT		
No CT	218	89.6
Normal	5	2.0
Abdominal fluid pressing on the liver -kidneys the	1	.4
lungs are not remarkable		
Atrophied kidney	1	.4
bi lateral hydronephrosis	1	.4
Bilateral atrophied kidneys	1	.4
Bilateral PKD	1	.4
Bilateral small atrophied kidneys with multiple cystic lesion	1	.4
both kidneys normal in size, with bilateral sever	1	.4
hydronephrosis no stones	4	4
Hydronephrosis due to staghorn stone in left kidney	1	.4
Left adrenal neuroblastoma with enlarged paraaortic and iliac lymph nodes	1	.4
markedly enlarged with ca deposition, poor corticomed differentiation and stretched deformed renal pelvis ( polycystic kidney disease )	1	.4
Medullary nephrocalcinosis with renal stones	1	.4
Multiple variable in size cortical cysts	1	.4
No renal vein thrombosis, small bowel edema and mild free fluid	1	.4
normal, high density in the cortex	1	.4
Rt kidney enlarge and severe hydronephrosis lef kidney with multiple cysts	1	.4
Severe hydronephrosis and hydroureter	1	.4
Splenomegaly	1	.4
The left side horseshoe kidney concerning for	1	.4
residual or recurrent tumor		.,
The right kidney has been surgically removed with no evidance of residual tumor or recurrence. Two	1	.4
cortical lesions seen in the left kidney.		
Unremarkable	1	.4
Variable sizes stone in the lower pole right kidney	1	.4

are not integral and important investigations were not performed such as eye examinations, assessment of kidney size, and ECHO.

Our results are consistent with the current literature; in age group up to 6 years, renal disorders followed by coarctation of the aorta are the most commonly reported causes, followed bythe renal parenchymal disease in older age.<sup>[11]</sup> In another study in the southwestern United States, out of 132 children with HTN, 67% was due to renal or renovascular diseases such as renal artery thrombosis, cystic kidney disease, glomerulonephritis, and reflux nephropathy.<sup>[12]</sup> In another study, underlying causesof secondary HTN in 242 patients were mostly due to chronic glomerulonephritis (49.2%), followed by coarctation of aorta, (53.3%) then obstructive uropathy (15.8%) and reflux nephropathy (12.2%) in contrast to low prevalence of thrombotic

Table 5: CVS finding			
Variable	n	Percentage	
No ECHO	157	65.5	
Normal	52	21.3	
7 mm fenestrated ASD shunting left to right	1	.4	
Cardiomyopathy	1	.4	
Coarctation of aorta	1	.4	
Dilated left ventricle and left atrium	1	.4	
IVC thrombus	1	.4	
Left ventricular dilation	1	.4	
Left ventricular hypertrophy	10	4.1	
Left ventricular hypertrophy + valvular lesion	1	.4	
Mild peripheral pulmonary stenosis	1	.4	
Minimal pericardial effusion and minimal pericardial thickening	1	.4	
Patent foramen ovale	1	.4	
PDA	2	.8	
Pericardial effusion	1	.4	
TGA,PDA S/P ARTERIAL switch operation	1	.4	
Tof dialted RV + pulmonary atresia/s/p tof repair and tricuspid valve repair and lpa unifocalization	1	.4	
Valvular lesion	6	2.5	
Valvular lesion, TOF	1	.4	
vsd	1	.4	

microangiopathy (6.1%) and renovascular disease (5.7%).<sup>[7]</sup> In a retrospective study in Thailand among 66 children, the prevalence of secondary HTN was 79.1% and most patients were asymptomatic, renal parenchymal diseases were identified in 62.7% and coarctation of the aorta was detected in 3.0% only.<sup>[13]</sup>

Previous studies have revealed that many factors are associated with the high rates of HTN such as age, sex (male) or obesity. In another study of 25,309 children and adolescents aged 7-18 years, the prevalence of obesity and HTN were 3.7% and 4.9%, respectively. A multicenter study by Narang et al. concluded that age, sex, socioeconomic status, and geographical distribution had an impact on the prevalence of HTN.<sup>[14]</sup> In 2017, Das Mk et al. reported that the prevalence of HTN raises with BMI and age. More specefically, the prevalence of HTN among under weight was 14.6% compared to 20.6% among normal weight persons.<sup>[15]</sup> In a cross-sectional study in northern India among 1,085 school children aged from 11 to 17 years, the prevalence of HTN and overweight were 5.9% and 3.5%, respectively.<sup>[16]</sup> However, Sumboonnanonda et al. found that BMI more than 25 is not reliable to differentiate primary and secondary HTN, since there is no significant difference between them.<sup>[13]</sup>

In general, systemic HTN could affect the cardiovascular system. In our study, left ventricular hypertrophy and valvular lesions were the highest abnormality reported, even with a few event and small prevalence reported. In a cross-section study on hypertensive young patients, 17% had concentric left ventricular hypertrophy.<sup>[17]</sup> However, Lesiman *et al.* found a humble relationship between blood pressure variability and left ventricular hypertrophy in primary and secondary HTN;

however, secondary HTN was associated with increased sleep period diastolic standard deviation.<sup>[18]</sup> Further, regular screening for elevated blood pressure and preventable measurement to control weight, reduce salt intake, encourage healthy dietary habits and active lifestyle are all recommended to avoid the complications of pediatric HTN.<sup>[1]</sup>

The main aim of healthcare practitioners in the management of pediatric secondary HTN is to normalize the blood pressure below the 90th percentile and closely monitor any potential target organ damage.<sup>[19]</sup> However, there is no preferred antihypertensive medication, but it is recommended to start with the lowest dosage of the antihypertensive medication till target blood pressure is reached. If still target blood pressure is not achieved with the maximum dosage of a single medication, a second medication with complementary action should be added.<sup>[19]</sup> In our study, the majority of patients were treated by angiotensin-converting enzyme inhibitor (ACEI), since it was found to be a good choice for a child with proteinuria due to renal disease.<sup>[19]</sup> Also, the highest percentage of patients who progressed to end-stage renal disease were managed by medications. Beside pharmacological therapy, lifestyle modification could be effective to decline the blood pressure. Significant reduction in blood pressure in adolescent was accomplished bymaintaining the DASH diet (Dietary Approaches to Stop HTN) versus standard diet.<sup>[20]</sup>

It is worth mentioning that evidence-based information and statistics about pediatric HTN would help the policymakers and all healthcare practitioners in the effective management of HTN and associated comorbidities. The National Institute of Health (NIH) of the USA has reported that at least once annual evaluation of blood pressure and checking the elements of anthropometry are warranted.<sup>[21,22]</sup>

Our study has some limitations: (1) it was carried out as a single-center, (2) participants were only inpatients cases, (3) investigations performed were not sufficient to evaluate and investigate the complications of HTN, and (4) there were some missing data from specific profiles.

## Conclusion

The prevalence of secondary HTN due to renal disease is considered to be high in pediatric patients admitted to King Abdulaziz University. Several renal diseases in the renal system are associated with secondary HTN mostly attributed to renal malformation. In addition, renal affection, cerebral infarction, bleeding, left ventricular hypertrophy, and valvular lesion are the highest reported complications in our population. Follow-up with ECHO and brain CT is highly recommended in pediatric HTN. Future studies on a larger sample and vigorous follow-up are recommended.

## Recommendations

 Follow-up extended studies with ECHO, eye examination and brain CT are highly recommended in pediatric HTN

Table 6: Brain finding		
Variable	n	Percentage
N/A	169	69.3
Normal	40	16.4
Associated with mass effect and midline shift - bilateral diffuse brain edema	1	.4
Atrophic brain changes	1	.4
Atrophy	1	.4
Bilateral focal area of vasogenic edema	1	.4
Bilateral globus palledi calcification likely related to renal disease and hemodialysis	1	.4
Bilateral occipital and temporal hypodensitis likely representing PRES disease	1	.4
bleeding	2	.8
Brain atrophic changes in form of dilated ventricle	1	.4
Could be A recent ischemic event, further evaluation by MRI is recommended	1	.4
Deep white matter hypodensity due to metabolic imbalance	1	.4
diffuse axonal injury	1	.4
Dilatation of lateral and 3rd ventricles	1	.4
Dilated lateral and third ventricle	1	.4
Early edema	1	.4
hypoxic ischemic injury	1	.4
Hyrdocephalous	1	.4
infarction	6	2.5
Internal placment of Lt posterior parietal VP shunt - fullness of the 4 <sup>th</sup> ventricle and the foramen magnum - interval increase of the size of the ventricular system	1	.4
interval increase in the degree of hydrocephals involving the lateral ventricle	1	.4
Large left retrocerebellar cyst in posterior fossa	1	.4
Lt parietemloral and Rt temporal occipital subgleal fluid collection most likely related to fluid infusion	1	.4
Marked thinning of the carpus callosum	1	.4
mass in the left cerebral hemisphere	1	.4
No intracerebral hematoma or extra Axial collection	1	.4
non communicating hydrocephalus	1	.4
There is interval development of relatively large right occipital cortical and subcortical hypodensity and smaller one on the left side	1	.4
There's a Lt parietal subcortical hypodensity with no mass effect in the ajacent sulci or midline shift its likely a chronic brain insult. No evidence of acute brain insult	1	.4
Tiny dense focus on the right cerebral lair hemisphere	1	.4
Widining of extraaxsial space	1	.4

Table 7: Disease progression and outcomes			
Variable	n	Percentage	
Controlled	79	32.4	
Deceased	24	10.1	
Did surgery	1	.4	
Loss of follow up	49	20.1	
Progressed to end stage renal disease, patient was managed by CIC	1	.4	
Progressed to end stage renal disease, patient was managed by hemodialysis	19	7.8	
Progressed to end stage renal disease, patient was managed by kidney transplantation	4	1.6	
Progressed to end stage renal disease, patient was managed by medications	20	8.2	
Progressed to end stage renal disease, patient was managed by peritoneal dialysis	17	7.0	
Recovered	11	4.5	
Transient	4	1.6	
Uncontrolled	15	6.1	

• Studies with larger sample and multi-centers approach are recommended.

## Financial support and sponsorship

Nil.

## **Conflicts of interest**

There are no conflicts of interest.

#### References

- 1. Kapur G, Mattoo TK. Primary hypertension in children. InPediatric Hypertension. Humana Press, Totowa, NJ. 2013. p. 295-308.
- 2. Li N, Wang M, Cao M. Summary of Secondary Hypertension. InSecondary Hypertension. Springer, Singapore. 2020. p. 3-21.
- 3. Gupta-Malhotra M, Banker A, Shete S, Hashmi SS, Tyson JE, Barratt MS, *et al.* Essential hypertension vs. secondary hypertension among children. Am J Hypertens 2015;28:73-80.
- 4. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll AE, Daniels SR, *et al.* Clinical practice guideline for screening and management of high blood pressure in children and adolescents. Pediatrics 2017;140:e20171904.

- 5. Silverstein DM, Champoux E, Aviles DH, Vehaskari VM. Treatment of primary and secondary hypertension in children. Pediatr Nephrol 2006;21:820-7.
- 6. Baracco R, Mattoo TK. Pediatric hypertensive emergencies. Curr Hypertens Rep 2014;16:456.
- 7. Hari P, Bagga A, Srivastava RN. Sustained hypertension in children. Indian Pediatr 2000;37:268-74.
- 8. Ahmed SM, Al Mansour M. A study on the prevalence of risk factors for diabetes and hypertension among school children in Majmaah, Kingdom of Saudi Arabia. J Public Health Res 2017;6:64-9.
- Hothan KA, Alasmari BA, Alkhelaiwi OK, Althagafi KM, Alkhaldi AA, Alfityani AK, *et al.* Prevalence of hypertension, obesity, hematuria and proteinuria amongst healthy adolescents living in Western Saudi Arabia. Saudi Med J 2016;37:1120-6.
- 10. Manios Y, Karatzi K, Protogerou AD, Moschonis G, Tsirimiagou C, Androutsos O, *et al.* Prevalence of childhood hypertension and hypertension phenotypes by weight status and waist circumference: The Healthy Growth Study. Eur J Nutr 2018;57:1147-55.
- 11. Raj M, Krishnakumar R. Hypertension in children and adolescents: Epidemiology and pathogenesis. Indian J Pediatr 2012;80:71-6.
- 12. Arar MY, Hogg RJ, Arant BSJ, Seikaly MG. Etiology of sustained hypertension in children in the southwestern United States. Pediatr Nephrol 1994;8:186-9.
- 13. Sumboonnanonda A, Chongcharoensuk C, Supavekin S, Pattaragarn A. Persistent hypertension in Thai children: Etiologies and outcome. J Med Assoc Thai 2006;89(Suppl 2):S28-32.
- 14. Narang R, Saxena A, Desai A, Ramakrishnan S, Thangjam RS,

Kulkarni S, *et al.* Prevalence and determinants of hypertension in apparently healthy schoolchildren in India: A multi-center study. Eur J Prev Cardiol 2018;25:1775-84.

- 15. Das MK, Bhatia V, Sibal A. Prevalence of hypertension in urban school children aged 5 to 10 years in North India. Int J Pediatr 2017;4:2055-9.
- Sharma A, Grover N, Kaushik S, Bhardwaj R, Sankhyan N. Prevalence of hypertension among schoolchildren in Shimla. Indian Pediatr 2010;47:873-6.
- 17. Daniels SR, Loggie JMH, Khoury P, Kimball TR. Left ventricular geometry and severe left ventricular hypertrophy in children and adolescents with essential hypertension. Circulation 1998;97:1907-11.
- Leisman D, Meyers M, Schnall J, Chorny N, Frank R, Infante L, et al. Blood pressure variability in children with primary vs secondary hypertension. J Clin Hypertens 2014;16:437-41.
- 19. Stabouli S, Redon J, Lurbe E. Redefining hypertension in children and adolescents: A review of the evidence considered by the European society of hypertension and American academy of pediatrics guidelines. J Hypertens 2020;38:196-200.
- 20. Bricarello LP, de Moura Souza A, de Almeida Alves M, Retondario A, Fernandes R, de Moraes Trindade EBS, *et al.* Association between DASH diet (Dietary approaches to stop hypertension) and hypertension in adolescents: A cross-sectional school-based study. Clin Nutr ESPEN 2020;36:P69-75.
- 21. Kumar P, Kumar D, Ranjan A, Singh CM, Pandey S, Agarwal N. Prevalence of hypertension and its risk factors among school going adolescents of Patna, India. J Clin Diagn Res 2017;11:SC01-4.
- 22. Fletcher RH, Fletcher SW, Fletcher GS. Clinical Epidemiology: The Essentials. Fifth.